ACADIA Pharmaceuticals Announces Positive Clinical Trial Results

ACADIA Pharmaceuticals Inc. reported the 19.04.2006 top-line results from a proof-of-concept clinical study that assessed the effect of ACP-103 on deep, or slow wave, sleep in healthy older volunteers using polysomnography (PSG). Results of the study demonstrated that ACP-103 induced a robust and statistically significant increase in slow wave sleep that was dose-related. ACP-103 treatment also had a positive impact on measures for sleep maintenance, including decreases in the number of awakenings after sleep onset and in the time awake after sleep onset. ACP-103 is ACADIA's proprietary serotonin 5-HT2A inverse agonist that blocks the activity of this key receptor.

Source: Press release ACADIA Pharmaceuticals Inc., 19.04.2006.

Read the press release at ACADIA Pharmaceuticals Inc. homepage